GSK-3β inhibitor 7

GSK-3β inhibitor 7 is a GSK-3β inhibitor with an IC50 value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder[1].

Product Specifications

UNSPSC

12352005

Target

GSK-3

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gsk-3β-inhibitor-7.html

Solubility

10 mM in DMSO

Smiles

CC1=CC=C(C=C1)S(=O)(N2C=C(C3=CC(Br)=CC=C32)C4=NC(NC5=C(C=CC=C5C)C)=NC=C4)=O

Molecular Formula

C27H23BrN4O2S

Molecular Weight

547.47

References & Citations

[1]Shuwen Han, et al. Structure-Based design of Marine-derived Meridianin C derivatives as glycogen synthase kinase 3β inhibitors with improved oral bioavailability: From aminopyrimidyl-indoles to the sulfonyl analogues. Bioorg Chem. 2022 Feb;119:105537.